Therapeutic effects and side effects of rifampicin administered daily or twice-weekly.
D000328:Adult; D001835:Body Weight; D004359:Drug Therapy, Combination; D004977:Ethambutol / Q000627:therapeutic use; D005076:Exanthema / Q000139:chemically induced; D005260:Female; D005334:Fever / Q000139:chemically induced; D005500:Follow-Up Studies; D005767:Gastrointestinal Diseases / Q000139:chemically induced; D006470:Hemorrhage / Q000139:chemically induced; D006801:Humans; D008297:Male; D008875:Middle Aged; D010146:Pain; D011718:Pyrazinamide / Q000627:therapeutic use; D012008:Recurrence; D012293:Rifampin / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D012769:Shock; D013183:Sputum / Q000382:microbiology; D013997:Time Factors; D014397:Tuberculosis, Pulmonary / Q000188:drug therapy* / Q000401:mortality
D011718:Pyrazinamide; D004977:Ethambutol; D012293:Rifampin